Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.52 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6338116 | 0.87 | CHRNB2 (0.50) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL766897 | 0.86 | MAPT (0.58) | BRD4CYSLTR2CYSLTR1LTA4HMAPT | |
| SCHEMBL13933053 | 0.86 | DGKA (0.53) | HTT | |
| SCHEMBL13933052 | 0.86 | DGKA (0.53) | HTT | |
| SCHEMBL6937314 | 0.84 | MEN1 (0.62) | BRD4CYSLTR2CYSLTR1LTA4HMAPT | |
| SCHEMBL3466988 | 0.83 | CYSLTR2 (0.59) | BRD4CYSLTR2CYSLTR1LTA4HMAPT | |
| SCHEMBL6778438 | 0.83 | GAA (0.62) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL8981963 | 0.83 | BRD4 (0.56) | BRD4CYSLTR2CYSLTR1LTA4HMAPT | |
| SCHEMBL22362132 | 0.82 | KMT2A (0.59) | BRD4CYSLTR2CYSLTR1LTA4HMAPT | |
| SCHEMBL12549253 | 0.81 | LTA4H (0.59) | BRD4CYSLTR2CYSLTR1LTA4HMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009797-A1 | Androstane derivative having substituent in 7- abd 17--positions | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009797-A1 | Androstane derivative having substituent in 7- abd 17--positions | NR5A1, CYP17A1, CYP19A1 | BRD4 1230/4885CYSLTR2 1637/4885CYSLTR1 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.